Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HUMANASDAQ:IMCRNASDAQ:INDVNASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$2.73-1.6%$1.72$1.15▼$9.97$425.80M1.643.80 million shs1.93 million shsIMCRImmunocore$36.24+3.4%$29.23$23.15▼$49.05$1.81B0.75390,789 shs72,288 shsINDVIndivior$12.85+3.5%$10.43$7.33▼$18.59$1.77B0.981.03 million shs633,755 shsSDGRSchrödinger$21.52+0.4%$22.70$16.60▼$28.47$1.58B1.84865,775 shs167,051 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte+5.32%+15.42%+93.71%-18.53%-64.07%IMCRImmunocore+11.27%+12.27%+15.00%+19.31%-23.33%INDVIndivior+3.07%+10.70%+5.62%+34.31%-31.21%SDGRSchrödinger-0.37%+1.04%-16.83%-3.90%+0.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHUMAHumacyte2.5349 of 5 stars3.51.00.00.03.52.50.6IMCRImmunocore2.9722 of 5 stars4.30.00.00.03.44.20.0INDVIndivior2.5571 of 5 stars2.63.00.00.02.61.71.9SDGRSchrödinger2.2713 of 5 stars3.51.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHUMAHumacyte 3.00Buy$11.71329.57% UpsideIMCRImmunocore 2.55Moderate Buy$58.8962.51% UpsideINDVIndivior 3.25Buy$15.0016.78% UpsideSDGRSchrödinger 3.00Buy$32.8052.42% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, SDGR, IMCR, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.004/7/2025IMCRImmunocoreMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.003/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHUMAHumacyte$517K818.20N/AN/A$0.13 per share20.98IMCRImmunocore$333.58M5.44N/AN/A$7.42 per share4.88INDVIndivior$1.17B1.51$2.60 per share4.94N/A∞SDGRSchrödinger$230.49M6.85$0.58 per share37.42$7.60 per share2.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHUMAHumacyte-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)IMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/14/2025 (Estimated)INDVIndivior$2M-$0.31N/A7.51N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)SDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)Latest HUMA, SDGR, IMCR, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHUMAHumacyteN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHUMAHumacyteN/A1.101.10IMCRImmunocore1.033.783.76INDVIndiviorN/A0.830.65SDGRSchrödingerN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHUMAHumacyte44.71%IMCRImmunocore84.50%INDVIndivior60.33%SDGRSchrödinger79.05%Insider OwnershipCompanyInsider OwnershipHUMAHumacyte5.10%IMCRImmunocore10.40%INDVIndiviorN/ASDGRSchrödinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHUMAHumacyte150155.12 million111.76 millionOptionableIMCRImmunocore32050.07 million45.48 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableSDGRSchrödinger79073.38 million66.59 millionOptionableHUMA, SDGR, IMCR, and INDV HeadlinesRecent News About These CompaniesFraud Investigation Opened: Levi & Korsinsky Investigates Schrdinger, Inc. (SDGR) on Behalf of ShareholdersMay 30 at 11:00 AM | accessnewswire.comVoloridge Investment Management LLC Cuts Holdings in Schrödinger, Inc. (NASDAQ:SDGR)May 30 at 4:02 AM | marketbeat.comAmeriprise Financial Inc. Has $2.67 Million Position in Schrödinger, Inc. (NASDAQ:SDGR)May 30 at 3:05 AM | marketbeat.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerMay 29 at 9:51 PM | finance.yahoo.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerMay 29 at 6:03 PM | businesswire.comSchrdinger, Inc. (SDGR) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky TodayMay 29 at 10:20 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to ConnectMay 29 at 10:00 AM | accessnewswire.comOngoing Schrdinger, Inc. (SDGR) Investigation: Protect Your Rights - Contact Levi & KorsinskyMay 28 at 2:15 PM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities InvestigationMay 28 at 10:00 AM | accessnewswire.comIntegrated Advisors Network LLC Sells 17,547 Shares of Schrödinger, Inc. (NASDAQ:SDGR)May 28 at 5:52 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $31.25 Million Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)May 28 at 4:48 AM | marketbeat.comBNP Paribas Financial Markets Makes New Investment in Schrödinger, Inc. (NASDAQ:SDGR)May 28 at 3:16 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRMay 27 at 12:00 PM | accessnewswire.comRXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?May 27 at 11:01 AM | zacks.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach OutMay 27 at 10:00 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to ConnectMay 26, 2025 | accessnewswire.comSchrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationMay 25, 2025 | accessnewswire.comMillennium Management LLC Raises Position in Schrödinger, Inc. (NASDAQ:SDGR)May 25, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRMay 24, 2025 | accessnewswire.comCaptrust Financial Advisors Takes $240,000 Position in Schrödinger, Inc. (NASDAQ:SDGR)May 24, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the InvestigationMay 23, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersAMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted GearsHUMA, SDGR, IMCR, and INDV Company DescriptionsHumacyte NASDAQ:HUMA$2.73 -0.04 (-1.55%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Immunocore NASDAQ:IMCR$36.24 +1.20 (+3.41%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Indivior NASDAQ:INDV$12.84 +0.44 (+3.51%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Schrödinger NASDAQ:SDGR$21.52 +0.08 (+0.37%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
